Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Clinical trial NCT03656094 · UNKNOWN

Trial details

NCT number: NCT03656094
Sponsor: Samsung Medical Center
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Metastatic

Start date: 2018-11-01
Primary completion: 2020-11-01
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.